CN1522147B - 含有15-酮基-前列腺素类化合物的用于治疗药物诱导的便秘的组合物 - Google Patents

含有15-酮基-前列腺素类化合物的用于治疗药物诱导的便秘的组合物 Download PDF

Info

Publication number
CN1522147B
CN1522147B CN028133897A CN02813389A CN1522147B CN 1522147 B CN1522147 B CN 1522147B CN 028133897 A CN028133897 A CN 028133897A CN 02813389 A CN02813389 A CN 02813389A CN 1522147 B CN1522147 B CN 1522147B
Authority
CN
China
Prior art keywords
group
constipation
keto
compound
morphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN028133897A
Other languages
English (en)
Chinese (zh)
Other versions
CN1522147A (zh
Inventor
上野隆司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23104042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1522147(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of CN1522147A publication Critical patent/CN1522147A/zh
Application granted granted Critical
Publication of CN1522147B publication Critical patent/CN1522147B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN028133897A 2001-05-02 2002-04-26 含有15-酮基-前列腺素类化合物的用于治疗药物诱导的便秘的组合物 Expired - Lifetime CN1522147B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28772001P 2001-05-02 2001-05-02
US60/287,720 2001-05-02
PCT/JP2002/004223 WO2002089812A1 (en) 2001-05-02 2002-04-26 Composition for treating drug-induced constipation with 15-keto-prostaglandins

Publications (2)

Publication Number Publication Date
CN1522147A CN1522147A (zh) 2004-08-18
CN1522147B true CN1522147B (zh) 2010-05-12

Family

ID=23104042

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028133897A Expired - Lifetime CN1522147B (zh) 2001-05-02 2002-04-26 含有15-酮基-前列腺素类化合物的用于治疗药物诱导的便秘的组合物

Country Status (19)

Country Link
US (1) US6982283B2 (enExample)
EP (1) EP1392318B1 (enExample)
JP (1) JP4332353B2 (enExample)
KR (1) KR100886598B1 (enExample)
CN (1) CN1522147B (enExample)
AR (2) AR035237A1 (enExample)
AT (1) ATE355067T1 (enExample)
AU (1) AU2002251554B2 (enExample)
BR (1) BR0209327A (enExample)
CA (1) CA2444103C (enExample)
DE (1) DE60218451T2 (enExample)
DK (1) DK1392318T3 (enExample)
ES (1) ES2282408T3 (enExample)
MX (1) MXPA03010019A (enExample)
NO (1) NO335143B1 (enExample)
NZ (1) NZ529187A (enExample)
PT (1) PT1392318E (enExample)
TW (1) TWI302100B (enExample)
WO (1) WO2002089812A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
WO2004037268A1 (en) * 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CN104248763A (zh) * 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2602812C (en) * 2005-04-12 2014-11-18 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US9044510B2 (en) 2007-11-01 2015-06-02 Washington University Compositions and methods for treating pruritus
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US8957024B2 (en) 2011-07-27 2015-02-17 Washington University Composition and methods for reducing opioid-induced pruritus
KR20140052389A (ko) 2012-10-24 2014-05-07 주식회사 아리바이오 해양 심층수 또는 염지하수로부터 제조된 고경도의 미네랄 워터를 포함하는 변비 예방, 개선 또는 치료용 조성물
US20140116916A1 (en) 2012-10-31 2014-05-01 2294719 Ontario Limited Therapy for Constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
CN105777601A (zh) * 2014-12-26 2016-07-20 中国人民解放军第二军医大学 一种前列地尔衍生物及其药物制剂
JP2019513355A (ja) * 2016-03-29 2019-05-30 コロナリーコンセプツ エルエルシー 便秘症を処置するための製剤
US11534404B2 (en) 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158062A (en) * 1977-05-26 1979-06-12 May & Baker Limited Cyclopentane derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
DE3873007T2 (de) * 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3187438B2 (ja) 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
PT1389116E (pt) * 2001-05-18 2008-04-11 Sucampo Ag Composição de indução catártica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158062A (en) * 1977-05-26 1979-06-12 May & Baker Limited Cyclopentane derivatives

Also Published As

Publication number Publication date
ATE355067T1 (de) 2006-03-15
TWI302100B (en) 2008-10-21
NO20034864L (no) 2003-12-23
US6982283B2 (en) 2006-01-03
EP1392318B1 (en) 2007-02-28
AR035237A1 (es) 2004-05-05
ES2282408T3 (es) 2007-10-16
NO20034864D0 (no) 2003-10-31
DE60218451T2 (de) 2007-11-08
NZ529187A (en) 2005-10-28
MXPA03010019A (es) 2004-02-12
JP2004527567A (ja) 2004-09-09
DK1392318T3 (da) 2007-06-25
AU2002251554B2 (en) 2007-05-24
CA2444103C (en) 2010-06-08
CA2444103A1 (en) 2002-11-14
EP1392318A1 (en) 2004-03-03
BR0209327A (pt) 2004-07-20
AR100696A2 (es) 2016-10-26
JP4332353B2 (ja) 2009-09-16
PT1392318E (pt) 2007-05-31
DE60218451D1 (de) 2007-04-12
KR20040008168A (ko) 2004-01-28
CN1522147A (zh) 2004-08-18
NO335143B1 (no) 2014-09-29
WO2002089812A1 (en) 2002-11-14
US20030073746A1 (en) 2003-04-17
KR100886598B1 (ko) 2009-03-05

Similar Documents

Publication Publication Date Title
CN1522147B (zh) 含有15-酮基-前列腺素类化合物的用于治疗药物诱导的便秘的组合物
US20100298424A1 (en) Method for treating abdominal discomfort
AU2002251554A1 (en) Composition for Treating Drug-Induced Constipation
US8114911B2 (en) Prostaglandin compounds for the treatment of obesity
TWI387454B (zh) 治療胃腸道疾病之方法及組成物
KR101760963B1 (ko) 종양 치료용 약제학적 조합물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20100512

CX01 Expiry of patent term